| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | Dear stakeholders, As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of 12099 - Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable. For information, the company have advised that they are not pursuing a Market Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. |
| Process | STA Standard |
| ID number | 12099 |
Project Team
| Project lead | Danielle Lees |
Email enquiries
- If you have any queries please email topic.selection@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 March 2025 | Suspended |
For further information on our processes and methods, please see our CHTE processes and methods manual